China’s WuXi Commits To Large Expansion Of Research, Reagent Spending

China's largest drug-research contractor, WuXi PharmaTech, plans to increase spending, perhaps doubling it, on laboratory equipment and reagents and other source materials, the company announced. The spending expansion, from the current $41.7 million, is being done to enlarge its research capacity and support U.S.-based AppTec Laboratory Services, whose $151 million purchase by WuXi just received U.S. Federal Trade Commission approval. To pay for the expansion, WuXi has asked for concessions by its suppliers. (Click here for more